Matrix metalloproteases(MMPs)and tissue inhibitors of matrix metalloproteases(TIMPs) have a co-regulation of changes of the extraeellular matrix(ECM).MMPs can control the proteases which are related to the process of tumor development.Moreover,MMPs,produced by host cells including inflammatory ceUs,endothelial cells,pericytes and fibroblasts have a positive or negative correlation with tumor formation.

Acupuncture treatment of insomnia has been reported for many years,but its validity remains controversial up to now.In the present review,the authors took "Acupuncture","Insomnia" as the key words to do a literature search from databases in both Chinese and English via computer retrieval system and also conducted a hand-made retrieval from journals of Chinese medicine as Chinese Acu-moxibustion,and collections of theses of the related academic conferences.Then,they made a systemic evaluation on the original articles from methodology,diagnosis,criteria for the enlisted and excluded patients,intervention methods of acupuncture and control groups,standards for assessing the curative efficacy,follow-up visit,etc.Of the retrieved 80 clinical articles,20 are RCT(randomized controlled trails) composed of 1907 cases,including 4 high-quality trails and 16 lower-quality trails.Regarding the assessment of the therapeutic effect,measuring scales are often adopted in overseas studies,while in domestic researches,self-drawn standards are frequently used.In conclusion,there have had no high-quality clinical trails about acupuncture treatment of primary insomnia in China at the present,and the related evaluating methods could not definitely confirm the efficacy of acupuncture in relieving insomnia.Therefore,a strict and scientific clinical trail scheme being in line with evidence-based medicine is urgently needed in the coming studies on acupuncture treatment of primary insomnia.

Objective To study the association of apolipoprotein ( Apo) E gene polymorphism with difference in biochemical metabolism of diabetic nephropathy of Hui and Han populations. Methods ApoE genotype was determined by PCR-RFLP in diabetic patients with or without diabetic nephropathy (DN) and normal peoples in Hui and Han peoples, the related biochemical parameters were simultaneously detected. Results (1) Huis had 3 genotypes, i. e. E2/E3, E3/E3 and E3/E4, and their frequencies were 0. 043, 0. 894 and 0. 064, respectively. Hans had 5 genetypes, i. e. E2/E2, E2/E3 , E2/E4, E3/E3 and E3/E4, and their frequencies were 0.075,0.060, 0.164, 0.642 and 0.060, respectively. The frequencies of 3 alleles, E2, E3 and E4, in Huis and Hans were 0.021, 0.947, 0.032 and 0.187, 0. 702, 0.112, respectively. The results showed that difference in frequencies of genotypes and alleles of Huis and Hans was very significant (both P

About half of the world population and more than 90% of rural households in the developing countries still use unprocessed biomass fuels (wood, dung and crop residues) as the fuels. These substances, burning in the open fire or in the simple stoves, can cause indoor air pollution and the pollutants exposure in women and children is more serious. Biomass smoke contains lots of toxic and harmful substances which may impact the health of human. This article presented a recent research progress in the indoor air pollution and health effects caused by combustion of biomass fuels in China and in the world.

Objective To investigate the nalaxone treating first acute right heart failure.Methods52 patients with FARHF were divided into the naloxone group(30cases)and control group(20cases)at random.Patients in control group were given general comprehensively treating.Patients in naloxone group were given naloxone as well as comprehensively treating,were given intravenously 0.8 mg of first dose,if it was necessary,repeated 0.8 mg of dose,and continuously dropped for 1.2 mg was added into liquid 500 mL.After treatment of 24 hours,were compared the changes of HR、SBP、SV and heart function.ResultsIn the naloxone group,the total effective rates were 84.4%,the mortality rates were 6.6%;in control group.The total effective rates were 60%,the mortality rates were 18.3%.The difference of the effective rate of the naloxone group be treatment was statistically significant(P

OBJECTIVE: To provide references for the improvement of drug safety of emergent public health events.METHODS: The characteristics of drug demands in emergent public health events were analyzed to guarantee the characteristics of drug safety so as to explore effective safeguard strategy.RESULTS & CONCLUSIONS: Special system and countermeasure are required to guarantee drug safety of emergent public health events.The strategy includes three aspects,i.e.adequate plan in advance,rapid response and timely consummation after the event.

Inflammatory bowel disease(IBD) is characterized by chronic non-specific inflammatory dis ease.The inflammation caused by abnormal immune response in intestinal mucosa exerts an important role in the pathogenesis of IBD.T helper 17 cells(Th17)are involved in the development of chronic inflammation and auto immune disease,whereas regulatory T cells can inhibit the function of autoimmune,and thus the balance of Th17/Treg balance plays an important role in intestinal homeostasis.Various strategies can be done to modulate Th17/Treg balance,such as antigen-presenting cells,microoganisms,some key molecules,natural compounds,proving a promising therapeutic method for IBD.

Climacteric syndrome is a common clinical disease with high incidence.The understanding of the disease is progressing in recent years.This article collects thirty-seven documents in this field in recent eight years.The pathogenesis of climacteric syndrome is divided into two aspects as the deficiency of the kidney and the imbalance of the liver, the spleen and the heart.It also sums up the therapy of climacteric syndrome from this two aspects.At last, the authors propose that we should pay attention to the importance of the liver, the spleen and the heart in both the pathogenesis and the therapy.

Inflammatory bowel disease is a chronic non-specific intestinal tract inflammation,currently,its etiology and pathogenesis are not clear.The current conventional treatments include salicylic acid drugs, steroids, immunosuppressive agents, biological agents and surgery, but the prognosis is still not very optimistic.In recent years, a variety of other treatment options have emerged, such as anti-cytokine antibody, anti-chemokine antibodies.Clinicians pay more attention to treatment of inflammatory bowel disease.

Objective To evaluate the efficacy and safety ofbevacizumab combined with FOLFIRI regimen as second-line treatment in advanced colorectal cancer.Methods Sixty-five advanced colorectal cancer patients previously treated with oxaliplatin were divided into test group(33 patients) and control group (32 patients) by random digits table method.The patients in test group received bevacizumab combined with FOLFIRI regimen chemotherapy.The patients in control group received FOLFIRI regimen chemotherapy only.The therapeutic effect was evaluated every 4 cycles.Results In test group,1 patient received complete remission,9 patients had partial remission,the rate of efficacy was 30.3％ (10/33).In control group,non patient had complete remission,3 patients received partial remission,the rate of efficacy was 9.4％ (3/32).The rate of efficacy between two groups had significant difference (x2 =4.45,P =0.035).The median duration of survival was 13.0 months in test group,and 10.3 months in control group(HR =0.58,P=0.038).The median progression-free survival duration was 7.5 months in test group,and 4.4 months in control group (HR =0.45,P =0.003).The median treatment cycle was 12 cycles in test group and 8 cycles in control group.The rate of Ⅲ/Ⅳ grade adverse events in test group was higher than that in control group[72.7％(24/33) vs.46.9％ (15/32)] (P ＜ 0.05).None of these events led to death during the study.Conclusions Bevacizumab combined with FOLFIRI as second-line treatment in advanced colorectal cancer can improve the total remission rate,and prolong the progression-free survival duration and total survival duration with an acceptable adverse reaction.